0000899243-20-031503.txt : 20201118
0000899243-20-031503.hdr.sgml : 20201118
20201118191754
ACCESSION NUMBER: 0000899243-20-031503
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201116
FILED AS OF DATE: 20201118
DATE AS OF CHANGE: 20201118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: VANDERVEEN RANDALL L
CENTRAL INDEX KEY: 0001197539
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 333-199861
FILM NUMBER: 201326605
MAIL ADDRESS:
STREET 1: BUILDING 4, TRIDENT PLACE
CITY: MOSQUITO WAY
STATE: X0
ZIP: AL10 9UL
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mylan II B.V.
CENTRAL INDEX KEY: 0001623613
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981189497
STATE OF INCORPORATION: P7
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BUILDING 4, TRIDENT PLACE, MOSQUITO WAY
CITY: HATFIELD, HERTFORDSHIRE
STATE: X0
ZIP: AL109UL
BUSINESS PHONE: 44 0 1707 853 000
MAIL ADDRESS:
STREET 1: BUILDING 4, TRIDENT PLACE, MOSQUITO WAY
CITY: HATFIELD, HERTFORDSHIRE
STATE: X0
ZIP: AL109UL
FORMER COMPANY:
FORMER CONFORMED NAME: Mylan N.V.
DATE OF NAME CHANGE: 20150227
FORMER COMPANY:
FORMER CONFORMED NAME: New Moon B.V.
DATE OF NAME CHANGE: 20141028
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-16
1
0001623613
Mylan II B.V.
MYL
0001197539
VANDERVEEN RANDALL L
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY
HATFIELD, HERTFORDSHIRE
X0
AL10 9UL
UNITED KINGDOM
1
0
0
0
Ordinary Shares
2020-11-16
4
M
0
9440
0.00
A
57227
D
Ordinary Shares
2020-11-16
4
D
0
57227
D
0
D
Restricted Stock Units
0.00
2020-11-16
4
M
0
9440
0.00
D
Ordinary Shares
9440
0
D
Non-Employee Director Stock Option - Right to Buy
45.72
2020-11-16
4
D
0
2974
D
2024-04-11
Ordinary Shares
2974
0
D
Non-Employee Director Stock Option - Right to Buy
50.66
2020-11-16
4
D
0
2603
D
2025-11-17
Ordinary Shares
2603
0
D
Non-Employee Director Stock Option - Right to Buy
46.27
2020-11-16
4
D
0
2788
D
2026-02-17
Ordinary Shares
2788
0
D
Non-Employee Director Stock Option - Right to Buy
45.18
2020-11-16
4
D
0
2928
D
2027-03-03
Ordinary Shares
2928
0
D
Non-Employee Director Stock Option - Right to Buy
40.97
2020-11-16
4
D
0
2984
D
2028-03-02
Ordinary Shares
2984
0
D
Non-Employee Director Stock Option - Right to Buy
27.45
2020-11-16
4
D
0
4352
D
2029-03-01
Ordinary Shares
4352
0
D
Non-Employee Director Stock Option - Right to Buy
17.48
2020-11-16
4
D
0
6151
D
2030-03-02
Ordinary Shares
6151
0
D
On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).
Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.
Each restricted stock unit ("RSU") represents the right to receive one ordinary share of Mylan. The RSUs vested in full on November 16, 2020 in connection with the conclusion of Dr. Vanderveen's service as a director on such date.
Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination.
These options vested on April 11, 2015.
These options vested on May 1, 2016.
These options vested on February 17, 2017.
These options vested on March 3, 2018.
These options vested on March 2, 2019.
These options vested on March 2, 2020.
These options vested in full on November 16, 2020 in connection with the conclusion of Dr. Vanderveen's service as a director on such date.
/s/ Kevin Macikowski, by power of attorney
2020-11-18